Biotechnology and cell therapy represent the cold chain at its most demanding. Where pharmaceutical products require temperature control to preserve chemical integrity, cell-based therapies require cold chain management to maintain biological viability — the difference between a product that works and one that is simply inert material. The margin between these outcomes is narrow, the consequences of excursion are absolute, and the value at stake per shipment can reach hundreds of thousands of dollars.
Australia’s biotechnology sector is growing rapidly. Clinical trials, cell manufacturing facilities, and biorepositories are distributed across major cities, while patients requiring these therapies may be in regional or remote locations. The cold chain connecting cell manufacturers to patients — whether for autologous CAR-T cells, allogeneic natural killer cells, tissue-engineered constructs, or stored biological samples — must function reliably across this geography.
Temperature Requirements Across Biotechnology Applications
Cryogenic Storage: -196°C (Liquid Nitrogen)
Cell-based therapies, stem cells, cord blood, and primary biological materials are typically cryopreserved at liquid nitrogen temperatures (-196°C). At this temperature, all biological activity is suspended. Cells can be stored indefinitely with minimal degradation — provided the cold chain is maintained.
The critical threshold is -130°C (the glass transition temperature of most cryoprotectant solutions). Above this temperature, cells begin transitioning from glassy solid state to mobile liquid state, allowing ice recrystallisation to occur. Ice crystal formation damages cell membranes and organelles, causing cell death on thawing. A cell therapy product that has breached -130°C even briefly may show normal morphology when thawed but have severely compromised viability, functionality, or both.
Ultra-Low Temperature: -80°C
Many biological reagents, research samples, RNA products, and some cell-based products are stored at -80°C (dry ice temperature). This temperature maintains product integrity for months and is achievable with dry ice as a shipping medium. -80°C storage does not provide the indefinite preservation available at liquid nitrogen temperatures, but is adequate for most research samples and short-term storage of some clinical products.
Dry ice shipping to -78.5°C is standard for -80°C product transport across Australia, particularly for research samples, biobank materials, and products where liquid nitrogen logistics are unavailable or impractical.
Refrigerated: 2–8°C
Cell therapies that are administered shortly after manufacture — particularly freshly manipulated T cells, dendritic cell vaccines, or short-lived biological products — may be shipped at 2–8°C rather than cryopreserved. These products have defined viability windows (typically 24–72 hours) and require temperature-controlled transport with tight monitoring and rapid delivery.
Controlled Room Temperature: 15–25°C
Some biologics, including certain antibody-drug conjugates and gene therapy vectors, require controlled room temperature rather than refrigeration. Temperature excursions in either direction (too cold or too warm) can compromise product integrity.
Dry Ice Logistics for Biotechnology Shipping
Dry ice (solid CO₂ at -78.5°C) is the workhorse thermal medium for biotechnology cold chain. (See our guide on dry ice sublimation rate and how to calculate CO₂ loss for planning your refrigerant orders.) in Australia. It is widely available, provides sustained sub-zero temperatures, requires no mechanical refrigeration, and is accepted by most courier services when properly packaged and documented.
Sizing Dry Ice Quantities
Dry ice sublimation rate depends on insulation quality and ambient conditions. For a step-by-step thermal load calculator, see How Many Dry Ice Packs Do I Actually Need? A general rule for Australian conditions:
- High-quality expanded polystyrene box with 25mm wall thickness: approximately 3–5% of dry ice mass sublimes per hour
- Purpose-built insulated shipper with vacuum panel insulation: 1–2% per hour
- Standard cardboard box (not recommended): 8–12% per hour
For a 24-hour transit, a 5kg dry ice load in a good EPS shipper typically provides adequate thermal mass with margin. For 48-hour transits, 8–10kg is advisable. Always validate with actual temperature mapping before deploying to clinical shipments.
Regulatory Requirements for Dry Ice Shipping
Dry ice is classified as a Dangerous Good (UN 1845, Class 9) for air transport. Australian regulations under IATA Dangerous Goods Regulations require:
- Shipper declaration (for quantities exceeding 2.5kg)
- Package marked with UN number, proper shipping name, and quantity
- Outer packaging must vent CO₂ (no hermetic seal)
- Maximum 200kg per package for passenger aircraft; unlimited for cargo aircraft
Ground transport regulations are less restrictive but still require proper labelling and ventilated vehicles for large quantities (CO₂ accumulation in enclosed spaces is an asphyxiation hazard).
Dry Chill Cryoblock for Biotech Shipping
Dry Chill Cryoblock dry ice packs provide the thermal performance of dry ice in a reusable, sealed format. For biotechnology applications where repeated shipping occurs (biobank sample transfers, multi-site clinical trial sample collection), reusable Cryoblocks reduce per-shipment dry ice procurement costs and improve consistency.
Liquid Nitrogen Logistics: The Clinical Cell Therapy Challenge
CAR-T cell therapies and other cryopreserved cell products manufactured at central facilities and shipped to treatment centres require liquid nitrogen logistics. This is substantially more complex than dry ice shipping:
- Liquid nitrogen shippers (dry vapour shippers) must be pre-charged with liquid nitrogen and can maintain vapour phase temperatures of -150°C or below for 5–10 days depending on shipper design
- Dry vapour shippers must be transported upright and have specific tilt limitations
- Liquid nitrogen is not accepted on commercial passenger aircraft; freight-only options are required
- Chain of custody documentation is required for clinical cell therapies — typically involving barcode tracking and real-time temperature monitoring at every handoff
For Australian clinical trials involving cell therapies, the cold chain typically involves certified courier services with specific liquid nitrogen handling protocols, ARTG-registered transport containers, and qualified personnel at each handoff point.
Temperature Monitoring for GMP Compliance
Good Manufacturing Practice (GMP) requirements for cell therapy products mandate documented temperature control. For a broader overview of Australian cold chain compliance obligations, see our guide to Cold Chain Compliance in Australia: What TGA, FSANZ and Safe Work Require. throughout the supply chain. The Therapeutic Goods Administration (TGA) aligns with EU GMP Annex 13 for investigational medicinal products, which requires:
- Continuous temperature monitoring throughout transport
- Defined temperature specifications and alert limits
- Documented procedures for temperature excursions, including impact assessment on product quality
- Validated shipping configurations based on temperature mapping studies
Temperature dataloggers placed in each shipment provide the continuous monitoring record required for GMP compliance. For clinical cell therapy products, USB dataloggers with tamper-evident features and time-stamped CSV output are typically required to generate the certificate of temperature compliance that accompanies each product.
Biorepository and Sample Management
Research biorepositories — biobanks, clinical trial sample archives, genomic collections — face cold chain challenges at both the storage and the distribution ends of the operation.
Sample collection from clinical sites requires validated collection kits that maintain samples at the correct temperature during transport to the central biorepository. Depending on the sample type, this may be 2–8°C (serum, plasma, many molecular samples), dry ice (-80°C for RNA and labile analytes), or ambient (some DNA samples). Standardised cold chain carriers appropriate to each sample type, pre-validated with temperature mapping studies, reduce variability and protocol deviations across collection sites.
Building a GMP-Ready Biotechnology Cold Chain in Australia
For biotechnology companies and clinical trial sponsors establishing Australian cold chain operations, the key elements are:
- Define the temperature requirement precisely — not just “frozen” but -80°C ± 10°C, -150°C vapour phase, or 2–8°C as the case demands
- Select validated shipping systems — use commercially validated shippers with published temperature performance data, or commission internal validation studies
- Establish monitoring requirements — select dataloggers appropriate to the temperature range and regulatory requirement
- Train personnel at every handoff point — most cold chain excursions occur at handoffs, not during transit
- Build a non-conformance process — define in advance what happens when a temperature excursion is detected
Dry Chill supplies dry ice, gel packs, insulated shipping containers, and temperature dataloggers to biotechnology operations across Australia. For pharmaceutical and biological cold chain requirements more broadly, see our article on cold chain packaging for vaccines and biologics. For cold chain consultation or product samples for your validation studies, contact our team.